^
    Back
    Association details:
    Biomarker:TTF1 expression
    Cancer:Lung Adenocarcinoma
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC-WCLC 2023
    Title:

    Clinical impact of TTF-1 for Combined Chemoimmunotherapy Efficacy in Lung Adenocarcinoma: A Multicenter Prospective Study

    Published date:
    08/08/2023
    Excerpt:
    The study demonstrated that the TTF-1 positive group had a significantly longer PFS and OS than the TTF-1 negative group (10.9 vs. 5.0 months, p = 0.01, not reached, p = 0.04, respectively).
    Secondary therapy:
    Chemotherapy